Physician profile
Carl B Wallach
NPI 1962593947
$41,407.39
in general payments reported to CMS, 2019-2025
48 companies · $5,485 in 2025
The $5,485 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,714 · 2020: $3,087 · 2021: $4,333 · 2022: $7,106 · 2023: $3,356 · 2024: $12K · 2025: $5,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $9,486 · Travel and Lodging: $1,249 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,300.00 |
| Food and Beverage | $9,486.30 |
| Travel and Lodging | $1,249.10 |
| Education | $130.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,761.73 | 2019-2025 | |
| Abbvie INC. | $7,427.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Allergan, INC. | $5,231.76 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,579.97 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Ironwood Pharmaceuticals, INC | $2,545.71 | 2019-2025 | Linzess |
| Janssen Biotech, INC. | $1,935.18 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $1,500.82 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $658.82 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $652.27 | 2019-2025 | |
| Qol Medical, LLC | $596.25 | 2022-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $515.44 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $475.41 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $465.72 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $402.85 | 2019-2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $401.83 | 2023-2025 | Zenpep |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $321.02 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $319.30 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $312.24 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $168.59 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $153.41 | 2019-2025 | Rebyota |
| Genzyme Corporation | $134.11 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $120.29 | 2021 | |
| Celltrion USA INC. | $118.90 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $90.96 | 2022-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $84.39 | 2019-2023 | Dificid |
| Vivus LLC | $65.48 | 2023-2024 | Qsymia, Pancreaze |
| Capsovision, INC. | $55.26 | 2023-2024 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $35.18 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $34.34 | 2023-2024 | Idacio |
| Becton, Dickinson and Company | $30.66 | 2022 | |
| Organon LLC | $29.21 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2023-2024 | Cyltezo |
| Medtronic, INC. | $20.93 | 2024 | Endoflip |
| Madrigal Pharmaceuticals | $19.77 | 2025 | Rezdiffra |
| Orphalan INC | $16.26 | 2024 | Cuvrior |
| Olympus America INC. | $15.74 | 2019 | |
| Ucb, INC. | $14.85 | 2019 | |
| Novo Nordisk INC | $14.71 | 2024 | |
| Glaxosmithkline, LLC. | $14.16 | 2020 | |
| Redhill Biopharma INC. | $13.67 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.61 | 2023 | Acanya |
| Alfasigma USA, INC. | $12.21 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Wallach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.